AMGN Amgen Inc.

237.6
-3.89  -2%
Previous Close 241.49
Open 240.97
Price To Book 12.92
Market Cap 141,178,009,342
Shares 594,183,541
Volume 3,094,111
Short Ratio
Av. Daily Volume 2,185,879
Stock charts supplied by TradingView

NewsSee all news

  1. Amgen Announces Global Diagnostic Collaborations To Expand Molecular Testing For Patients With Non-Small Cell Lung Cancer

    THOUSAND OAKS, Calif., Jan. 13, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced strategic collaborations with leading diagnostic companies Guardant Health, Inc. and QIAGEN N.V. to develop blood- and tissue-based

  2. Amgen To Present At The 38th Annual J.P. Morgan Healthcare Conference

    THOUSAND OAKS, Calif., Jan. 9, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 38th Annual J.P. Morgan Healthcare Conference at 8:30 a.m. PT on Tuesday, Jan. 14, 2020, in San Francisco. Robert A.

  3. Amgen To Present At The Goldman Sachs 12th Annual Healthcare CEOs Unscripted Conference

    THOUSAND OAKS, Calif., Jan. 7, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present via video conference at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted Conference at 1 p.m. PT on Thursday, Jan. 9, 2020.

  4. BeiGene Announces Closing of Amgen Global Strategic Oncology Collaboration and Equity Investment

    Amgen Completes Purchase of Approximately $2.8 Billion of BeiGene SharesAnthony C. Hooper, Former Executive Vice President of Global Commercial Operations at Amgen, Joins BeiGene Board of Directors CAMBRIDGE, Mass. and

  5. Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China

    THOUSAND OAKS, Calif., Jan. 2, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the successful closing of the transaction to enter into a strategic collaboration with BeiGene that will significantly accelerate

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due late-2020.
Tezepelumab - NAVIGATOR
Asthma
Approval announced May 21, 2018.
Prolia (denosumab)
Glucocorticoid-induced osteoporosis (GIOP)
sNDA approval announced June 11, 2018.
KYPROLIS (ASPIRE)
Relapsed Multiple Myeloma
sBLA approval announced June 29, 2017.
Vectibix (Panitumumab)
Wild-Type RAS Metastatic Colorectal Cancer
Approved September 14, 2017.
MVASITM (bevacizumab-awwb)
Biosimilar candidate to Avastin (bevacizumab)
Approved April 15, 2015.
Corlanor
Chronic Heart Failure
Approval announced May 17, 2018.
Erenumab
Migraine
Phase 3 ongoing. Expected completion 2024.
CNP 520
Alzheimer’s Disease
sNDA filing pending.
OTEZLA
Scalp Psoriasis
Phase 3 - primary endpoint met.
OTEZLA - PSA-006
Psoriatic Arthritis
FDA Approval announced July 19, 2019.
OTEZLA
Behçet’s Disease
Approval announced December 1, 2017.
Repatha
Cardiovascular disease
sBLA approval announced January 5, 2017.
XGEVA
Multiple Myeloma
FDA approval announced October 1, 2018.
KYPROLIS (ARROW)
Multiple Myeloma
sNDA approved January 17, 2018.
KYPROLIS (ENDEAVOR)
Relapsed Multiple Myeloma
PDUFA date under priority review August 14, 2017. Approval announced July 11, 2017.
BLINCYTO
Ph+ R/R ALL
BLA filing announced December 19, 2019.
ABP 798
RITUXAN biosimilar - non-Hodgkin lymphoma
FDA approval announced June 13, 2019.
ABP 980 (Kanjinti; trastuzumab-anns)
Herceptin biosimilar
FDA Approval announced December 6, 2019.
ABP 710
REMICADE biosimilar - rheumatoid arthritis
Approved February 7, 2017.
Parsabiv
Secondary hyperparathyroidism (SHPT)
FDA Approval announced April 9, 2019.
EVENITY (Romosozumab)
Osteoporosis
Phase 3 second interim analysis due 1Q 2020. Top-line data due 4Q 2020.
Omecamtiv mecarbil GALACTIC-HF
Acute heart failure
Second Phase 3 trial initiation announced February 21, 2019. Enrolment to continue through 2020.
Omecamtiv mecarbil METEORIC-HF
Acute heart failure
Phase 1 data ASCO June 2, 2019. Overall response rate 70% (7/10) in high dose, 13/42 response across all cohorts.
AMG 420
Relapsed. Refractory (R/R) Multiple Myeloma (MM)
Phase 1 data at ASH December 1, 2018 noted 12.5% ORR.
AMG 330
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
FDA approval announced December 14, 2018.
Nplate (Romiplostim)
Immune Thrombocytopenia (Pediatric)
FDA Approval announced October 18, 2019.
Nplate (Romiplostim)
Immune thrombocytopenia (ITP)
Phase 3 data met primary endpoint - September 13, 2019. LBA at ASH December 10, 2019. PFS HR=0.63. ORR 84.3%. CR 28.5%.
KYPROLIS (CANDOR)
Multiple Myeloma
Phase 3 trial is initiating.
OTEZLA - ADVANCE
Plaque psoriasis
Phase 1 trial to be completed 2H 2020.
AMG 594
Healthy volunteers
Phase 1 update at ESMO noted 54% PR rate for NSCLC patients (960mg); 1/12 for CRC patients. Next update due in 2020.
AMG 510
Solid tumors
Phase 2/3 trial discontinued due to lack of efficacy.
CNP520
Alzheimer’s Disease
Phase 3 enrolment terminated due to treatment benefit over chemo. Primary endpoint of event-free survival met.
BLINCYTO
Acute lymphoblastic leukemia (ALL) - pediatric
Phase 2 trial is enrolling.
AMG 570
Systemic Lupus Erythematosus (SLE)
Phase 2 trial is enrolling.
Tezepelumab
Chronic obstructive pulmonary disease (COPD)

Latest News

  1. Amgen Announces Global Diagnostic Collaborations To Expand Molecular Testing For Patients With Non-Small Cell Lung Cancer

    THOUSAND OAKS, Calif., Jan. 13, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced strategic collaborations with leading diagnostic companies Guardant Health, Inc. and QIAGEN N.V. to develop blood- and tissue-based

  2. Amgen To Present At The 38th Annual J.P. Morgan Healthcare Conference

    THOUSAND OAKS, Calif., Jan. 9, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 38th Annual J.P. Morgan Healthcare Conference at 8:30 a.m. PT on Tuesday, Jan. 14, 2020, in San Francisco. Robert A.

  3. Amgen To Present At The Goldman Sachs 12th Annual Healthcare CEOs Unscripted Conference

    THOUSAND OAKS, Calif., Jan. 7, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present via video conference at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted Conference at 1 p.m. PT on Thursday, Jan. 9, 2020.

  4. BeiGene Announces Closing of Amgen Global Strategic Oncology Collaboration and Equity Investment

    Amgen Completes Purchase of Approximately $2.8 Billion of BeiGene SharesAnthony C. Hooper, Former Executive Vice President of Global Commercial Operations at Amgen, Joins BeiGene Board of Directors CAMBRIDGE, Mass. and

  5. Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China

    THOUSAND OAKS, Calif., Jan. 2, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the successful closing of the transaction to enter into a strategic collaboration with BeiGene that will significantly accelerate

  6. Amgen And Allergan Submit Biologics License Application For ABP 798, Biosimilar Candidate To Rituxan® (rituximab), To U.S. Food And Drug Administration

    THOUSAND OAKS, Calif., Dec. 19, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA)

  7. European Commission Approves EVENITY® (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture

    THOUSAND OAKS, Calif. and BRUSSELS, Dec. 11, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the European Commission (EC) has granted marketing authorization for EVENITY®

  8. Amgen Announces 10% Increase In 2020 First Quarter Dividend

    THOUSAND OAKS, Calif., Dec. 11, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.60 per share dividend for the first quarter of 2020. The dividend will be paid on March

  9. Amgen Data From Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) To Be Presented During Late-Breaking Session At American Society Of Hematology Annual Meeting

    THOUSAND OAKS, Calif., Dec. 10, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced additional results from the primary analysis of the Phase 3 CANDOR study evaluating KYPROLIS® (carfilzomib) in combination with

  10. Beyond Cholesterol: Landmark deCODE Study Elucidates Role of Lipoprotein(a) as Major Risk Factor for Heart Disease

    REYKJAVIK, Iceland, Dec. 9, 2019 /PRNewswire/ -- Scientists at deCODE genetics and colleagues from the National University Hospital in Iceland today present the largest-scale study to date of the role and public health

  11. Amgen Selects Location For R&D Facility In The South San Francisco Biotechnology Hub

    THOUSAND OAKS, Calif., Dec. 9, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the signing of a lease with BioMed Realty for a new 240,000-square-foot Leadership in Energy and Environmental Design (LEED)

  12. FDA Approves Amgen's AVSOLA™ (infliximab-axxq), For The Same Indications As Remicade® (infliximab)

    THOUSAND OAKS, Calif., Dec. 6, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved AVSOLA™ (infliximab-axxq) for all approved indications of the

  13. Abarca, Amgen Enter Outcome-Based Agreement For Enbrel

    AVENTURA, Fla., Dec. 3, 2019 /PRNewswire/ -- Abarca, a pharmacy benefit manager (PBM) that is disrupting the industry with an entirely new approach to technology and business practices, today announced it has entered

  14. Amgen Announces Data Being Presented At ASH 2019

    THOUSAND OAKS, Calif., Dec. 2, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new clinical data from its oncology in-line products and pipeline that will be presented at the 61st American Society of Hematology

  15. Amgen Completes Acquisition Of Otezla® (apremilast)

    THOUSAND OAKS, Calif., Nov. 21, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the successful completion of its acquisition of worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for

  16. Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company

    Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all government authorities required by

  17. New Results From COSMIC-HF Presented at AHA 2019 Show Treatment of Heart Failure Patients With Omecamtiv Mecarbil Was Associated With Neutral or Improved Measures of Diastolic Function

    THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. and SURESNES, France,, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN), Cytokinetics, Incorporated (NASDAQ:CYTK) and Servier announced that new results from

  18. Amgen Announces New FOURIER Analysis Showing Benefit Of Repatha® (evolocumab) In High-Risk Patients Who Have Experienced A Recent Heart Attack

    THOUSAND OAKS, Calif., Nov. 16, 2019 /PRNewswire/ -- Amgen today announced a new analysis from the Repatha® (evolocumab) cardiovascular outcomes (FOURIER) study that evaluates the effectiveness of Repatha in patients who

  19. Bristol-Myers Squibb Receives Clearance from U.S. Federal Trade Commission for Celgene Acquisition

    Company Has Now Satisfied All Regulatory Approvals for Celgene Acquisition Transaction Expected to Close on November 20, 2019 FTC Approves Agreement between Celgene and Amgen to Divest OTEZLA® Bristol-Myers Squibb

  20. Amgen And The Duke Clinical Research Institute Announce Initiation Of First Large-Scale Registry To Evaluate Real-World Lipid Management And The Effectiveness Of PCSK9 Inhibitors

    THOUSAND OAKS, Calif., Nov. 15, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) in collaboration with the Duke Clinical Research Institute (DCRI) today announced plans to initiate the Cardiovascular Multi-dimensional

  21. Amgen Highlights Data To Be Presented At AHA 2019 Across Cardiovascular Portfolio

    THOUSAND OAKS, Calif., Nov. 11, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from its cardiovascular portfolio will be presented at the American Heart Association (AHA) Scientific Sessions 2019

  22. Amgen To Present At The 28th Annual Credit Suisse Healthcare Conference

    THOUSAND OAKS, Calif., Nov. 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 28th Annual Credit Suisse Healthcare Conference at 9:45 a.m. MT on Tuesday, Nov. 12, 2019, in Scottsdale, Ariz. David W.

  23. Amgen Enters Into Strategic Collaboration With BeiGene To Expand Oncology Presence In China

    THOUSAND OAKS, Calif., Oct. 31, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that it has entered into a strategic collaboration with BeiGene that will significantly accelerate Amgen's plans to expand its

  24. BeiGene Announces Global Strategic Oncology Collaboration with Amgen

    • Companies to Collaborate on the Commercialization of XGEVA® (denosumab), KYPROLIS® (carfilzomib), and BLINCYTO® (blinatumomab) in China  • Companies to Jointly Develop 20 Amgen Oncology Pipeline Assets, with BeiGene

  25. The Discovery Of Amgen's Novel Investigational KRAS(G12C) Inhibitor AMG 510 Published In Nature

    THOUSAND OAKS, Calif., Oct. 30, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced a publication in Nature unveiling the discovery of AMG 510, a small molecule inhibitor of KRASG12C being investigated as a

  26. Amgen Recommends Rejection Of 'Mini-Tender' Offer From TRC Capital Corporation

    THOUSAND OAKS, Calif., Oct. 23, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has been notified of an unsolicited "mini-tender" offer dated Oct. 11, 2019, made by TRC Capital Corporation, a

  27. David Meline, Amgen's Chief Financial Officer, To Retire

    THOUSAND OAKS, Calif., Oct. 22, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the planned retirement of David W. Meline, who has served as the company's executive vice president and chief financial officer

  28. Amgen Announces 2019 Fourth Quarter Dividend

    THOUSAND OAKS, Calif., Oct. 22, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.45 per share dividend for the fourth quarter of 2019. The dividend will be paid on Dec.

  29. Nplate® (romiplostim) Now Approved For Earlier Use In Adults With Immune Thrombocytopenia

    THOUSAND OAKS, Calif., Oct. 18, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved Amgen's Supplemental Biologics License Application (sBLA) for Nplate®

  30. Sports Anchor And Multiple Myeloma Patient Rod Gilmore Joins Amgen's Myeloma MVP™ Team

    THOUSAND OAKS, Calif., Oct. 15, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the expansion of Myeloma MVP™, a national initiative to help myeloma patients and their care teams create their Most Valuable Plan.

  31. Amgen Foundation Launches Amgen Biotech Experience In Pittsburgh

    THOUSAND OAKS, Calif. and PITTSBURGH, Oct. 9, 2019 /PRNewswire/ -- The Amgen Foundation today announced the launch of the Amgen Biotech Experience (ABE) program in Pittsburgh, Pa. Through a grant from the Richard King

  32. Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Patients With Solid Tumors At ESMO 2019

    THOUSAND OAKS, Calif., Sept. 27, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the ongoing Phase 1 study evaluating AMG 510 in patients with previously treated KRAS G12C-mutant solid tumors. The

  33. Heart Attack Survivors Are Taking Steps To Reduce Their Cardiovascular Risk. But Are They The Right Ones?

    THOUSAND OAKS, Calif., Sept. 26, 2019 /PRNewswire/ -- In recognition of World Heart Day on Sunday, September 29, Amgen (NASDAQ:AMGEN) today released findings from a global survey that evaluated worldwide heart attack

  34. Amgen To Webcast Investor Call At ESMO 2019

    THOUSAND OAKS, Calif., Sept. 25, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society for Medical Oncology (ESMO) 2019 Congress on

  35. Amgen Announces Positive Results From Two Phase 3 BLINCYTO® (blinatumomab) Studies In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia

    THOUSAND OAKS, Calif., Sept. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial

  36. Amgen Showcases New Data From Oncology Pipeline And Portfolio At ESMO 2019

    THOUSAND OAKS, Calif., Sept. 17, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from its oncology pipeline and marketed product portfolio will be presented at the European Society for Medical

  37. S&P 500 buybacks decline significantly in Q2 2019; expenditures still remain higher than the pre-2018 levels

    NEW YORK, Sept. 16, 2019 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") announced today that preliminary Q2 2019 S&P 500® stock buybacks, or share repurchases, were $164.5 billion. This was the

  38. Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference

    THOUSAND OAKS, Calif., Sept. 13, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:45 a.m. British Summer Time on Wednesday, Sept. 18, 2019, in

  39. Amgen Announces Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) Meets Primary Endpoint Of Progression-Free Survival

    THOUSAND OAKS, Calif., Sept. 13, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Phase 3 CANDOR study evaluating KYPROLIS® (carfilzomib) in combination with dexamethasone and DARZALEX® (daratumumab) (KdD)

  40. Amgen Highlights New Data From KYPROLIS® (carfilzomib) And Oncology Pipeline At IMW 2019

    THOUSAND OAKS, Calif., Sept. 12, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from its oncology portfolio and pipeline will be presented at the 17th International Myeloma Workshop (IMW) 2019 in

  41. deCODE in Iceland Agrees to Sequence Half of UK Biobanks Participants

    REYKJAVIK, Iceland, Sept. 11, 2019 /CNW/ -- deCODE genetics in Iceland has entered into an agreement with a consortium of government, charity, researchers and world leading biopharmaceutical and healthcare companies to

  42. deCODE in Iceland Agrees to Sequence Half of UK Biobanks Participants

    REYKJAVIK, Iceland, Sept. 11, 2019 /PRNewswire/ -- deCODE genetics in Iceland has entered into an agreement with a consortium of government, charity, researchers and world leading biopharmaceutical and healthcare

  43. Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Larger Patient Group At WCLC 2019

    THOUSAND OAKS, Calif., Sept. 8, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the ongoing Phase 1 study evaluating AMG 510 in patients with previously treated KRAS G12C-mutated solid tumors. AMG

  44. Amgen To Present At The Morgan Stanley Global Healthcare Conference

    THOUSAND OAKS, Calif., Sept. 5, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley Global Healthcare Conference at 9:10 a.m. ET on Tuesday, Sept. 10, 2019, in New York City. Robert A. Bradway,

  45. Amgen To Webcast Investor Call At IASLC 2019 World Conference on Lung Cancer

    THOUSAND OAKS, Calif., Sept. 4, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community at the International Association for the Study of Lung Cancer (IASLC) 2019 World Conference

  46. New Amgen Data To Be Presented At ESC Congress 2019 Highlight Additional Evidence For Repatha® (Evolocumab) Effectiveness In Cardiovascular Disease Across Multiple Patient Groups

    THOUSAND OAKS, Calif., Aug. 28, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of 14 cardiovascular scientific research abstracts, including studies evaluating the safety and efficacy of

  47. Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits

    THOUSAND OAKS, Calif., Aug. 26, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that it has entered into an agreement with Celgene Corporation (NASDAQ:CELG) in connection with its previously announced

  48. Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4 Billion

    Agreement Contingent on FTC Consent Decree and Closing of Pending Bristol-Myers Squibb-Celgene Merger Pending Bristol-Myers Squibb-Celgene Merger Expected to Close by End of 2019 Bristol-Myers Squibb Company